C4 Therapeutics saw the highest growth of 1.19% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.19% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of C4 Therapeutics‘s patent filings and grants. Buy the databook here.
C4 Therapeutics has been focused on protecting inventions in China(CN) with seven publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 33% filings and 50% grants. The China(CN), European Patent Office(EPO), United States(US), and Chile(CL) patent Office are among the top ten patent offices where C4 Therapeutics is filings its patents. Among the top granted patent authorities, C4 Therapeutics has 50% of its grants in China(CN) and 50% in United States(US).
Roche could be the strongest competitor for C4 Therapeutics
Patents related to rare diseases and climate change lead C4 Therapeutics's portfolio
C4 Therapeutics has the highest number of patents in rare diseases followed by, climate change and cell & gene therapy. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Colorectal tumor related patents lead C4 Therapeutics portfolio followed by lung cancer, and ovarian cancer
C4 Therapeutics has highest number of patents in colorectal tumor followed by lung cancer, ovarian cancer, pancreatic cancer, and thyroid cancer.
For comprehensive analysis of C4 Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.